AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca rare Disease (Alexion) — Worldwide product sales ($M) ($M)
Form 6-K Quarterly & Form 20-F Product Sales by Therapy Area & Region Tables
Latest, FY2025
9,126
Period ended Dec 31, 2025
Change on a year earlier
+5.3%
8,668 in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rare Disease (Alexion) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9,126 | +5.3% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 8,668 | +11.6% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 7,764 | +10.1% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 7,053 | +129.7% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 3,070 | – | Form 6-K FY2021Q4 Earnings Release ↗ |
Breakdown
What makes up rare disease (alexion) — worldwide product sales ($m)
- Rare Disease (Alexion) — Worldwide YoY actual (%)5.0% · FY2025
- Rare Disease (Alexion) — Worldwide YoY CER (%)5.0% · FY2025
- Rare Disease (Alexion) — US product sales ($M)5,423 · FY2025
- Rare Disease (Alexion) — Emerging Markets product sales ($M)1,038 · FY2025
- Rare Disease (Alexion) — Europe product sales ($M)1,604 · FY2025
- Rare Disease (Alexion) — Established RoW product sales ($M)1,061 · FY2025
- Ultomiris (ravulizumab) — Worldwide product sales ($M)4,718 · FY2025
- Soliris (eculizumab) — Worldwide product sales ($M)1,837 · FY2025
- Strensiq (asfotase alfa) — Worldwide product sales ($M)1,678 · FY2025
- Koselugo (selumetinib) — Worldwide product sales ($M)662 · FY2025
- Other Rare Disease medicines — Worldwide product sales ($M)231 · FY2025
Cite this data
StockData. (2026). AstraZeneca Rare Disease (Alexion) — Worldwide product sales ($M) ($M), annual FY2021–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta_rare_world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.